The estimated Net Worth of Samuel R Md Nussbaum is at least $227 Thousand dollars as of 16 February 2018. Samuel Nussbaum owns over 10,000 units of Coherus Biosciences Inc stock worth over $13,300 and over the last 10 years he sold CHRS stock worth over $0. In addition, he makes $213,902 as Independent Director at Coherus Biosciences Inc.
Samuel has made over 4 trades of the Coherus Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CHRS stock worth $50,000 on 16 February 2018.
The largest trade he's ever made was exercising 49,340 units of Coherus Biosciences Inc stock on 13 April 2015 worth over $3,654,614. On average, Samuel trades about 4,959 units every 65 days since 2015. As of 16 February 2018 he still owns at least 10,000 units of Coherus Biosciences Inc stock.
You can see the complete history of Samuel Nussbaum stock trades at the bottom of the page.
Dr. Samuel R. Nussbaum M.D. serves as Independent Director of the Company. Dr. Nussbaum has served on our Board of Directors since March 2018. Dr. Nussbaum currently serves as a Strategic Consultant to EBG Advisors and a Senior Advisor to Sandbox Industries and to the Ontario Teachers’ Pension Plan. Dr. Nussbaum is a Professor of Clinical Medicine at Washington University School of Medicine, an adjunct professor at the Olin School of Business, Washington University and a Senior Fellow at the USC Schaeffer Center for Health Policy and Economics. From 2000 until 2016, Dr. Nussbaum served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer for Anthem. Dr. Nussbaum received his B.A. from New York University and his M.D. from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital. Nussbaum is qualified to serve on our Board of Directors based on his extensive experience in the health care industry.
As the Independent Director of Coherus Biosciences Inc, the total compensation of Samuel Nussbaum at Coherus Biosciences Inc is $213,902. There are 11 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.
Samuel Nussbaum is 71, he's been the Independent Director of Coherus Biosciences Inc since 2018. There are 1 older and 14 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
Samuel's mailing address filed with the SEC is C/O PROGENITY, INC., 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO, CA, 92122.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle, and James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: